viking therapeutics dark horse glp-1 | Biotechnology Watch Out, Eli Lilly and

Animal experiments received approval from the Ethical Committee (No

Subunit-specific rules governing AMPA receptor trafficking to synapses in hippocampal pyramidal neurons

We see Novo Nordisk and Eli Lilly as overvalued despite assuming that a quarter of US adults with obesity will be on GLP-1 therapies by 2031, leading to a GLP-1 market north of $200 billion in 2031, before generic semaglutide (Wegovy/Ozempic/Rybelsus) launches. Competition rises

Nicotinamide mononucleotide, an NAD+ precursor, rescues age-associated susceptibility to AKI in a sirtuin 1-dependent manner

Scalp psoriasis is one of the most common complaints at DermaVue Kottayam

Alpinia officinarum (galangal): A beneficial plant